Európska únia - slovenčina - EMA (European Medicines Agency)

seqirus s.r.l.  - povrchové antigény vírusu chrípky (hemaglutinín a neuraminidáza) kmeňa: a / turkey / turkey / 1/05 (h5n1) -like kmeň (nibrg-23) - influenza, human; immunization; disease outbreaks - vakcíny - aktívna imunizácia proti podtypu h5n1 vírusu chrípky-a. tento údaj je založený na immunogenicity údaje zo zdravých subjektov, od veku 18 rokov a ďalej po podaní lieku dve dávky vakcíny obsahujúce/turecko/turkey/1/05 (h5n1)-ako kmeň. aflunov by mali byť použité v súlade s oficiálne odporúčania.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mylan ireland limited, Írsko - metoprolol - 58 - hypotensiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

merck sharp & dohme b.v., holandsko - očkovacia látka proti pneumokokom, purifikovaný polysacharidový antigén - 59 - immunopraeparata

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva b.v., holandsko - diklofenak - 29 - antirheumatica, antiphlogistica, antiuratica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva b.v., holandsko - diklofenak - 29 - antirheumatica, antiphlogistica, antiuratica

Európska únia - slovenčina - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vakcíny - active immunisation against h5 subtype of influenza a virus.

Slovensko - slovenčina - Ecolab

ecolab deutschland gmbh -

Európska únia - slovenčina - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vakcíny - aktívna imunizácia proti ochorenie spôsobené streptococcus pneumoniae sérotypy 4, 6b, 9v, 14, 18 c, 19f a 23f (vrátane sepsy, meningitídy, pneumónia, bakterémia a akútna otitis media) u dojčiat a detí od dvoch mesiacov až päť rokov. použitie prevenar by mali byť stanovené na základe oficiálnych odporúčaní, berúc do úvahy vplyv invazívnych ochorení v rôznych vekových skupinách, ako aj variabilita sérotyp epidemiológie v rôznych geografických oblastiach.

Európska únia - slovenčina - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - ošípané - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Európska únia - slovenčina - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunologické prístroje pre sviňovité - ošípané (pre výkrm) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.